Kenny Manion, MD
Family Medicine · Glasgow, KYNPI 1518951896
Payments from drug & device makers
Across 99 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$255
- GSK$179
- Pfizer$175
- AbbVie$173
- Takeda Pharmaceuticals U.S.A., Inc.$154
- Lilly USA, LLC$105
- plus $481 from 15 others
What the payments were for
- Food & beverage$1,522100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $255 |
| GSK | 13 | $179 |
| Pfizer | 11 | $175 |
| AbbVie(2 entities) | 12 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $154 |
| Lilly USA, LLC | 7 | $105 |
| Boehringer Ingelheim | 7 | $104 |
| Amgen | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Shire North American Group Inc | 2 | $29 |
| Novo Nordisk | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Vertex | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
How this compares
$1,522 in reported general payments places this provider in the 60th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $40,450 |
| JardianceEmpagliflozin | 43 | $33,286 |
| OzempicSemaglutide | 35 | $33,126 |
| EliquisApixaban | 19 | $17,713 |
| LinzessLinaclotide | 21 | $13,116 |
| TrulicityDulaglutide | 13 | $12,337 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $12,236 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 39 | $11,687 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 50 | $10,193 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,348 |
| FarxigaDapagliflozin Propanediol | 16 | $8,766 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,061 |
| BrilintaTicagrelor | 13 | $7,219 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,593 |
| VascepaIcosapent Ethyl | 17 | $6,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Shingrix | $179 | $62,330154 claims |
| Boehringer IngelheimJardiance | $104 | $33,28643 claims |
| Novo NordiskOzempic | $29 | $33,12635 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $255 | $22,57859 claims |
| PfizerEliquis, Premarin | $175 | $22,45533 claims |
| AbbVieLinzess | $173 | $13,11621 claims |
| Lilly USA, LLCTrulicity, Humalog | $105 | $13,05324 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $154 | $12,89733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Glasgow
- Brad MalloryGlasgow$31K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.